Ayúdanos a dar forma a GoConqr. ¿Qué deberíamos añadir?

Fichas

Feb 4 Tues

Shylla T Inglés 47 fichas

Fichas del conjunto (47)

  1. 1PlasmalogenFA at position 1 is an unsaturated alkyl group attached to glycerol by ether (rather than an ester) linkage
    Phosphatidalethanolamine
    phosphatidalcholine
  2. 2Phosphatidalethanolamine phosphatidalcholineis abundant in nerve tissue
    in cardiac muscle
  3. 3Platelet-Activating Factorfirst signaling pthway in response to inflammtory signal
    Promotes oxidative burst of leukocytes (white blood cells) associated with host defense
  4. 4Cardiolipin Biosynthesis 2 stepsActivation of phosphatidic acid by CTP to from CDP-DAG
    Condensation with glycerol 3-phosphate to form PG-P
  5. 5Cardiolipin Biosynthesis next 2 stepsHydrolysis of phosphoester bond to form phosphatidylglycerol (PG)
    Condensation with activated DAG (i.e., CDP-DAG) to form cardiolipin (CL)
  6. 6Cardiolipinimporant for attaching compelxes in ETC
    Facilitates maintenance of proton motive force and anchors cyt c to inner mitochondrial membrane
  7. 7Phosphatidylinositol (PI) synthesizied frominositol and CDP-diacylglycerol,
  8. 8PIa reservoir of arachidonic acid, precursor for
    Phosphorylation of PI produces PIP2
  9. 9PIP2 gives way toDAG and IP3
  10. 10Arachidonic acidbecomes porataglandin thru action of cyclooxygenase enzymes (COX1 and COX2)
    becomes leukotrienes thru action of lipoxgenase (LOX)
  11. 11Prostaglandin synthesis is inhibited byInhibition of phospholipase A2 (cortisol; steroidal anti-inflammatory).
    Aspirin (NSAID) acetylates active site and inhibits both COX1 and COX2.
    Celecoxib (NSAID) selectively inhibits COX2.
  12. 12prostaglandin is imporantin inflammaotry response to inbiting it would inhibit infammation response
  13. 13Aspirin Inhibits cyclooxygenase 1 (COX1) byacetylating Ser530 that blocks active site Tyr385 to block arachidonic acid binding (and blocks thrombosis).
    Inhibits cyclooxygenase 2 (COX2) by a similar mechanism.
  14. 14OH group at carbon 1 of sphingosine is esterified tophosphorylcholine
    sphingomyelin
  15. 15Degradation of SphingomyelinSphingomyelinase removes phosphorylcholine.
    Accumulation of sphingomyelin in lysosomes (lysosomal storage disease).
  16. 16Niemann-Pick DiseaseAccumulation of sphingomyelin in lysosomes (lysosomal storage disease) becus sphoinomyelinase defincency
  17. 17Niemann-Pick Disease affectNo treatments for type A (severe disorder): death in early childhood
    Results in loss of myelin in CNS (main pathology)
  18. 18surfactantsProduced by type II alveolar epithelial cells in the lungs
    ---Lipids, protein and carbohydrates
    Surfactant lipids form a monolayer
  19. 19Surfactants in infantsPreterm infants with immature lungs are surfactant deficient
    Develop respiratory distress syndrome
  20. 20Composition of SurfactantDipalmytoyl phosphatidylcholine (DPPC) or dipalmitoyl lecithin is the highest among lipids
  21. 21Surfactant types ProteinsHydrophilic glycoproteins
    SP-A (~35 kDa)
    SP-D (~43 kDa)
    Hydrophobic proteins
    SP-B (~8.7 kDa)
    SP-C (~4.2 kDa)
  22. 22Surfactant Protein C (SP-C)Facilitates monolayer spreading
    and recruitment of lipids to
    the surface films
  23. 23Surfactant Protein B (SP-B)SP-B deficiency due to gene mutations
    are associated with respiratory distress
    in neonatal period
  24. 24Surfactant Proteins A and D structureOctadecameric SP-A and
    dodecameric SP-D
    SP-A has six trimers
    SP-D has four trimers
    SP-A and D bind lipids
  25. 25SP-A participates inorganizing alveolar surfactant phospholipids
  26. 26SP-A and Dhave a major role in regulating immune and inflammatory response
  27. 27SP-Bis required for assembly and its extracellular development
    ----Deficiency of SP-B is incompatible with life
  28. 28SP-B mutations associate withfatal respiratory distress syndrome in neonates
  29. 29Life Cycle of Pulmonary SurfactantBiosynthesis and processing of phospholipids and proteins
    ER and Golgi bodies
    Transported to and stored (except SP-A) in
    Lamellar bodies (LB)
    -LB have a limiting lamellar bilayer membrane
    -Limiting membrane fuses with plasma membrane
  30. 30life cycle part 2Contents released
    -PL associates with proteins and assemble onto SP-A to form tubular myelin (TM)
    -TM formation is calcium dependent
    -At high pressure and low lung volume desorption and endocytosis of components occurs
  31. 31Lung maturity of the fetus is determined bythe ratio of DPPC to sphingomyelin (L/S ratio)
    L/S ratio of >2.0 indicates lung maturity
    A major shift occurs in the synthesis from sphingomyelin to DPPC at about 32 weeks of gestation
  32. 32Lung Maturity TestsL/S ratio
    -Lecithin (PC) and sphingomyelin from amniotic fluid by TLC
    -Fluorescence polarization of amniotic lipids
    -Foam stability index
    -Lamellar body count
  33. 33Vascular Resistanceinput pressure - output pressure
    blood flow (same as systemic circulation)
  34. 34Pulmonary Vascular Resistance (PVR) is1/10 of SVR
  35. 35Comparing to the systemic circulation, the pulmonary circulation:Circulating pressures are remarkably low.
    Pulmonary vascular resistance is remarkably low.
    Blood vessel walls are thin at all levels.
    Containing far less smooth muscles.
  36. 36Majors factors affect pulmonary vascular resistance (PVR)-Changing cardiac output
    -Changing lung volume
    -Hydrostatic pressure
    of the blood vessels
    -Reducing the alveolar PO2
  37. 37Changing cardiac outputDuring exercise cardiac output increases (e.g. 5-fold), but with little change in mean pulmonary artery pressure.
  38. 38In order to keep pressure unchanged, the PVR mustdecrease
    by
    Recruitment: Opening of previously collapsed capillaries
    Distension: Increase in diameter of open capillaries.
  39. 39Effect of lung volume on PVRPVR is lowest near FRC and increases at both high and low lung volume because of the combined effects on the alveolar and extra-alveolar vessels.
  40. 40Zone 2Effective driving pressure is
    Pa – PA.
  41. 41Zone 3Effective driving pressure is
    Pa – Pv.
  42. 42zone 1little blood flow
  43. 43Effect of decreased alveolar PO2 on pulmonary blood flow.Decrease in alveolar PO2 leads to an increase in pulmonary vascular resistance (PVR), and as a result disease in pulmonary blood flow
  44. 44Hypoxic pulmonary vasoconstriction (HPV)Alveolar hypoxia constricts small pulmonary arteries and increases PVR.
    HPV leads to pulmonary hypertension.
    Directs blood flow away from poorly ventilated areas of the diseases lung, e.g. pulmonary edema.
    General hypoxemia (high altitude or hypoventilation) can cause extensive pulmonary artery vasoconstriction.
  45. 45V/Q mismatchis a condition in which one or more areas of the lung receive oxygen but less/no blood flow, or they receive blood flow but less/no oxygen due to some diseases and disorders.
  46. 46V/Q mismatch causeshypoxemia.
  47. 47—

Información

Descripción
Fichas sobre Feb 4 Tues, creado por Shylla T el 04/02/2020.
Creado por
Shylla T
Visitas
4
Valoración

Escríbenos

¿Sobre qué es tu mensaje?

¿Qué deberíamos añadir?